Table 2. LDL cholesterol levels at baseline and after treatment with rosuvastatin monotherapy or rosuvastatin/ezetimibe combination therapy.
| Variables | R20 (n=132) | RE10/10 (n=126) | Mean difference (standard error) | 95% confidence interval | p-value | |
|---|---|---|---|---|---|---|
| LDL-C at baseline (mg/dL), median [Min, Max] | 78.5, [34, 192] | 79.5, [32, 209] | 0.425* | |||
| At 12 wk | ||||||
| LDL -C at 12 wk (mg/dL) | 66.7 (20.5) | 60.5 (24.1) | ||||
| Absolute changes (mg/dL) | −14.3 (22.9) | −22.9 (38.1) | ||||
| Diabetes status | 0.086† | |||||
| % change‡ (%) | −15.6 (2.5) | −22.9 (2.6) | −7.4 (3.6) | −14.4 to −0.3 | 0.041§ | |
| At 24 wk | ||||||
| LDL-C at 24 wk (mg/dL) | 68.6 (22.19) | 60.9 (25.8) | ||||
| Absolute changes (mg/dL) | −11.4 (28.6) | −23.8 (31.4) | ||||
| Diabetes status | 0.016† | |||||
| % change∥ (%) | −12.9 (2.4) | −24.2 (2.5) | −11.3 (3.5) | −18.1 to −4.5 | 0.001§ | |
R20, high intensity statin group which received 20 mg of rosuvastatin once daily; RE10/10, combination therapy group which received 10 mg rosuvastatin and 10 mg ezetimibe once daily; LDL-C, low-density lipoprotein cholesterol.
*Difference between control and treatment groups (Wilcoxon rank sum test); †Difference between diabetic and nondiabetic patients using the ANCOVA model including baseline LDL-C as a covariate; ‡Percent change from baseline at week 12(%) = {(LDL-C after 12 weeks)−(LDL-C at baseline)}/(LDL-C at baseline)×100; §Difference between control and treatment groups using the ANCOVA model including baseline LDL-C and diabetic status as covariates; ∥Percent change from baseline at week 24(%) = {(LDL-C after 24 weeks)−(LDL-C at baseline)}/(LDL-C at baseline)×100.